|
π
|
Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy
11 auth.
Z. Hijazi,
J. Oldgren,
U. Andersson,
S. Connolly,
M. Ezekowitz,
S. Hohnloser,
...
P. Reilly,
D. Vinereanu,
A. Siegbahn,
S. Yusuf,
L. Wallentin
|
8 |
2012 |
8
π
|
|
π
|
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis
11 auth.
Z. Hijazi,
S. Hohnloser,
J. Oldgren,
U. Andersson,
S. Connolly,
J. Eikelboom,
...
M. Ezekowitz,
P. Reilly,
A. Siegbahn,
S. Yusuf,
L. Wallentin
|
8 |
2013 |
8
π
|
|
π
|
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
15 auth.
Z. Hijazi,
L. Wallentin,
A. Siegbahn,
U. Andersson,
C. Christersson,
J. Ezekowitz,
B. Gersh,
M. Hanna,
S. Hohnloser,
J. Horowitz,
...
K. Huber,
E. Hylek,
R. Lopes,
J. McMurray,
C. Granger
|
7 |
2013 |
7
π
|
|
π
|
The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.
11 auth.
R. Sandhu,
J. Ezekowitz,
U. Andersson,
J. Alexander,
C. Granger,
S. Halvorsen,
...
M. Hanna,
Z. Hijazi,
P. JanskΓ½,
R. Lopes,
L. Wallentin
|
7 |
2016 |
7
π
|
|
π
|
Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
12 auth.
L. Wallentin,
Z. Hijazi,
U. Andersson,
J. Alexander,
R. de Caterina,
M. Hanna,
...
J. Horowitz,
E. Hylek,
R. Lopes,
S. Γ
sberg,
C. Granger,
A. Siegbahn
|
7 |
2014 |
7
π
|
|
π
|
High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
15 auth.
Z. Hijazi,
L. Wallentin,
A. Siegbahn,
U. Andersson,
J. Alexander,
D. Atar,
B. Gersh,
M. Hanna,
V. Harjola,
J. Horowitz,
...
S. Husted,
E. Hylek,
R. Lopes,
J. McMurray,
C. Granger
|
7 |
2014 |
7
π
|
|
π
|
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.
12 auth.
Z. Hijazi,
S. Hohnloser,
U. Andersson,
J. Alexander,
M. Hanna,
M. Keltai,
...
A. Parkhomenko,
J. LΓ³pez-SendΓ³n,
R. Lopes,
A. Siegbahn,
C. Granger,
L. Wallentin
|
7 |
2016 |
7
π
|
|
π
|
High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
15 auth.
Z. Hijazi,
A. Siegbahn,
U. Andersson,
C. Granger,
J. Alexander,
D. Atar,
B. Gersh,
Puneet Mohan,
V. Harjola,
J. Horowitz,
...
S. Husted,
E. Hylek,
R. Lopes,
J. McMurray,
L. Wallentin
|
6 |
2013 |
6
π
|
|
π
|
Dβdimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation β observations from the ARISTOTLE trial
15 auth.
C. Christersson,
L. Wallentin,
U. Andersson,
John H. Alexander,
Jack Ansell,
R. Caterina,
B. J. Gersh,
Christopher B Granger,
M. Hanna,
John D. Horowitz,
...
Kurt Huber,
S. Husted,
E. Hylek,
Renato D. Lopes,
A. Siegbahn
|
6 |
2014 |
6
π
|
|
π
|
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.
14 auth.
J. Alexander,
U. Andersson,
R. Lopes,
Z. Hijazi,
S. Hohnloser,
J. Ezekowitz,
S. Halvorsen,
M. Hanna,
P. Commerford,
W. RuΕΌyΕΕo,
...
K. Huber,
S. AlβKhatib,
C. Granger,
L. Wallentin
|
6 |
2016 |
6
π
|
|
π
|
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
10 auth.
J. Aulin,
A. Siegbahn,
Z. Hijazi,
M. Ezekowitz,
U. Andersson,
S. Connolly,
...
K. Huber,
P. Reilly,
L. Wallentin,
J. Oldgren
|
6 |
2015 |
6
π
|
